Becker's Healthcare March 14, 2024
On March 14, the FDA approved the nation’s first medication to treat noncirrhotic non-alcoholic steatohepatitis with fibrosis, or fatty liver scarring.
Also known as MASH, or metabolic dysfunction-associated steatohepatitis, the condition is associated with other health conditions, including high blood pressure and Type 2 diabetes. Federal estimates place the prevalence between 6 million and 8 million people, which is expected to increase.
Madrigal Pharmaceuticals’ Rezdiffra (resmetirom) is indicated for MASH adult patients with moderate to advanced liver scarring to be used along with diet and exercise.
In a trial, between 24% and 36% of study participants experienced MASH resolution and did not see worsened liver scarring, compared to between 9% and 13% of those who received a...
Today's Sponsors
Today's Sponsor